These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 30883733)
1. TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2α as a therapeutic target. Chen LY; Huang RL; Chan MW; Yan PS; Huang TS; Wu RC; Suryo Rahmanto Y; Su PH; Weng YC; Chou JL; Chao TK; Wang YC; Shih IM; Lai HC J Pathol; 2019 Jul; 248(3):363-376. PubMed ID: 30883733 [TBL] [Abstract][Full Text] [Related]
2. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma. Norris EJ; Zhang Q; Jones WD; DeStephanis D; Sutker AP; Livasy CA; Ganapathi RN; Tait DL; Ganapathi MK J Pathol; 2019 Jul; 248(3):352-362. PubMed ID: 30883751 [TBL] [Abstract][Full Text] [Related]
3. Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions. Wu RC; Wang P; Lin SF; Zhang M; Song Q; Chu T; Wang BG; Kurman RJ; Vang R; Kinzler K; Tomasetti C; Jiao Y; Shih IM; Wang TL J Pathol; 2019 May; 248(1):41-50. PubMed ID: 30560554 [TBL] [Abstract][Full Text] [Related]
4. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906 [TBL] [Abstract][Full Text] [Related]
5. Increased expression of protein kinase CK2α correlates with poor patient prognosis in epithelial ovarian cancer. Ma Z; Wang X; He J; Xia J; Li Y PLoS One; 2017; 12(3):e0174037. PubMed ID: 28355289 [TBL] [Abstract][Full Text] [Related]
6. TET1 inhibits EMT of ovarian cancer cells through activating Wnt/β-catenin signaling inhibitors DKK1 and SFRP2. Duan H; Yan Z; Chen W; Wu Y; Han J; Guo H; Qiao J Gynecol Oncol; 2017 Nov; 147(2):408-417. PubMed ID: 28851501 [TBL] [Abstract][Full Text] [Related]
7. ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer. Jung M; Gao J; Cheung L; Bongers A; Somers K; Clifton M; Ramsay EE; Russell AJ; Valli E; Gifford AJ; George J; Kennedy CJ; Wakefield MJ; Topp M; Ho GY; ; Scott CL; Bowtell DD; deFazio A; Norris MD; Haber M; Henderson MJ Int J Cancer; 2020 Oct; 147(8):2225-2238. PubMed ID: 32277480 [TBL] [Abstract][Full Text] [Related]
8. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma]. Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967 [No Abstract] [Full Text] [Related]
9. Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer. Hooda J; Novak M; Salomon MP; Matsuba C; Ramos RI; MacDuffie E; Song M; Hirsch MS; Lester J; Parkash V; Karlan BY; Oren M; Hoon DS; Drapkin R Cancer Res; 2019 Feb; 79(4):760-772. PubMed ID: 30563893 [TBL] [Abstract][Full Text] [Related]
10. TET1-mediated DNA hydroxymethylation activates inhibitors of the Wnt/β-catenin signaling pathway to suppress EMT in pancreatic tumor cells. Wu J; Li H; Shi M; Zhu Y; Ma Y; Zhong Y; Xiong C; Chen H; Peng C J Exp Clin Cancer Res; 2019 Aug; 38(1):348. PubMed ID: 31399111 [TBL] [Abstract][Full Text] [Related]
12. Tubal origin of ovarian cancer - the double-edged sword of haemoglobin. Lin SF; Gerry E; Shih IM J Pathol; 2017 May; 242(1):3-6. PubMed ID: 28054715 [TBL] [Abstract][Full Text] [Related]
13. TET1 promotes cisplatin-resistance via demethylating the vimentin promoter in ovarian cancer. Han X; Zhou Y; You Y; Lu J; Wang L; Hou H; Li J; Chen W; Zhao L; Li X Cell Biol Int; 2017 Apr; 41(4):405-414. PubMed ID: 28150354 [TBL] [Abstract][Full Text] [Related]
14. The activation of microRNA-520h-associated TGF-β1/c-Myb/Smad7 axis promotes epithelial ovarian cancer progression. Zhang J; Liu W; Shen F; Ma X; Liu X; Tian F; Zeng W; Xi X; Lin Y Cell Death Dis; 2018 Aug; 9(9):884. PubMed ID: 30158641 [TBL] [Abstract][Full Text] [Related]
15. TET1 inhibits gastric cancer growth and metastasis by PTEN demethylation and re-expression. Pei YF; Tao R; Li JF; Su LP; Yu BQ; Wu XY; Yan M; Gu QL; Zhu ZG; Liu BY Oncotarget; 2016 May; 7(21):31322-35. PubMed ID: 27121319 [TBL] [Abstract][Full Text] [Related]
16. Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas. Soong TR; Howitt BE; Miron A; Horowitz NS; Campbell F; Feltmate CM; Muto MG; Berkowitz RS; Nucci MR; Xian W; Crum CP J Pathol; 2018 Nov; 246(3):344-351. PubMed ID: 30043522 [TBL] [Abstract][Full Text] [Related]
17. Long noncoding RNA TC0101441 induces epithelial-mesenchymal transition in epithelial ovarian cancer metastasis by downregulating KiSS1. Qiu JJ; Lin XJ; Tang XY; Zheng TT; Zhang XY; Hua KQ Int J Cancer; 2020 May; 146(9):2588-2598. PubMed ID: 31577838 [TBL] [Abstract][Full Text] [Related]
19. Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma. Chui MH; Doodnauth SA; Erdmann N; Tiedemann RE; Sircoulomb F; Drapkin R; Shaw P; Rottapel R Cancer Res; 2019 Nov; 79(21):5536-5549. PubMed ID: 31530568 [TBL] [Abstract][Full Text] [Related]
20. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]